RT Journal Article
T1 Safety and efficacy of G2-S16 dendrimer as microbicide in healthy human vaginal tissue explants.
A1 Rodríguez-Izquierdo, I
A1 Serramía, M J
A1 Gómez, R
A1 Espinosa, G
A1 Genebat, M
A1 Leal, M
A1 Muñoz-Fernandez, M A
K1 Efficacy
K1 G2-S16
K1 HIV-1
K1 Microbicide
K1 Safety
K1 Vaginal explants
AB The absence of an effective treatment and vaccine in HIV-1 pandemic place preventive strategies such as safety and effective microbicide development as a central therapeutic approach to control HIV-1 pandemic nowadays. Studies of cytotoxicity, immune population status, inflammation or tissue damage and mainly prophylactic inhibition of HIV-1 infection in vaginal human explants demonstrate the biosafety and effectivity of G2-S16 dendrimer. Human explants treated with G2-S16 dendrimer or treated and HIV-1 infected do not presented signs of irritation, inflammation, immune activation or T cell populations deregulation. Herein we conclude that G2-S16 dendrimer has demonstrated sufficient efficacy, biosafety, effectivity and behavior in the closest to the real-life condition model represented by the human healthy donor vaginal tissue explants, to raise G2-S16 dendrimer as a promising candidate to clinical trials to develop an effective microbicide against HIV-1 infection.
YR 2022
FD 2022-03-21
LK http://hdl.handle.net/10668/20323
UL http://hdl.handle.net/10668/20323
LA en
DS RISalud
RD Apr 5, 2025